Wang Yong1, Wei Shibo, Liu Jingang. 1. Department of General Surgery, Shengjing Hospital, China Medical University, 36 Sanhao Street, Shenyang, 110004 Liaoning, China. wangy@sj-hospital.org
Abstract
BACKGROUND: Gastric bypass surgery and exenatide therapy represent two relatively new methods in treating morbid obesity and type 2 diabetes, although there are many differences between them. With the data supported from our hospital, we just want to investigate the differences between bypass surgery and exenatide injection and want to answer the question: Which one is the best? And Why? METHODS: Data from January 2009 to January 2010 were summarized for comparison at Shengjing hospital, including weight loss, plasma glucose and insulin changes, glycosylated hemoglobin, and the subjective scores of patients themselves. Plasma lipoprotein and serum ions were measured to evaluate the nutrition status. RESULTS: Patients in the GB group received more weight loss and better glucose control compared with the EX group. At 6 months, feeding insulin level in the GB group was 18.1 ± 3.2 mU/L, which was much lower than that in the EX group (64.5 ± 13.2 mU/L, P < 0.01). The Hb1AC level in the GR group was 6.08 ± 0.56 %, much lower than that in the EX group (7.19 ± 0.72 %, P < 0.01). We did not find any statistical differences in lipoprotein, plasma ions, and subjective scores between the GB and EX groups. CONCLUSIONS: Gastric bypass surgery is better in weight control and in the remission of insulin resistance compared with exenatide therapy. Both methods were safe and have no nutritional disorder in early stage, although the transferring in the GB group was higher than the EX group. The subjective scores from both groups declared that both methods could be accepted by patients.
BACKGROUND: Gastric bypass surgery and exenatide therapy represent two relatively new methods in treating morbid obesity and type 2 diabetes, although there are many differences between them. With the data supported from our hospital, we just want to investigate the differences between bypass surgery and exenatide injection and want to answer the question: Which one is the best? And Why? METHODS: Data from January 2009 to January 2010 were summarized for comparison at Shengjing hospital, including weight loss, plasma glucose and insulin changes, glycosylated hemoglobin, and the subjective scores of patients themselves. Plasma lipoprotein and serum ions were measured to evaluate the nutrition status. RESULTS:Patients in the GB group received more weight loss and better glucose control compared with the EX group. At 6 months, feeding insulin level in the GB group was 18.1 ± 3.2 mU/L, which was much lower than that in the EX group (64.5 ± 13.2 mU/L, P < 0.01). The Hb1AC level in the GR group was 6.08 ± 0.56 %, much lower than that in the EX group (7.19 ± 0.72 %, P < 0.01). We did not find any statistical differences in lipoprotein, plasma ions, and subjective scores between the GB and EX groups. CONCLUSIONS: Gastric bypass surgery is better in weight control and in the remission of insulin resistance compared with exenatide therapy. Both methods were safe and have no nutritional disorder in early stage, although the transferring in the GB group was higher than the EX group. The subjective scores from both groups declared that both methods could be accepted by patients.
Authors: Juliana C N Chan; Vasanti Malik; Weiping Jia; Takashi Kadowaki; Chittaranjan S Yajnik; Kun-Ho Yoon; Frank B Hu Journal: JAMA Date: 2009-05-27 Impact factor: 56.272
Authors: Melek C Arkan; Andrea L Hevener; Florian R Greten; Shin Maeda; Zhi-Wei Li; Jeffrey M Long; Anthony Wynshaw-Boris; Giuseppe Poli; Jerrold Olefsky; Michael Karin Journal: Nat Med Date: 2005-01-30 Impact factor: 53.440
Authors: R A Pittner; C X Moore; S P Bhavsar; B R Gedulin; P A Smith; C M Jodka; D G Parkes; J R Paterniti; V P Srivastava; A A Young Journal: Int J Obes Relat Metab Disord Date: 2004-08
Authors: Romano Schneider; Marko Kraljević; Ralph Peterli; Theresa V Rohm; Jennifer M Klasen; Claudia Cavelti-Weder; Tarik Delko Journal: Obes Surg Date: 2020-06-05 Impact factor: 4.129